Bayer’s Next Growth Bet Rests on Wheat Genetics as Fitch Keeps the Pressure On
Published on 07/17/2026 at 03:43 | Redaktion boerse-global.de
Bayer is trying to open a new front in its agriculture business just as investors are weighing legal relief against a still-fragile balance sheet. The Leverkusen group has signed an exclusive licensing deal with French seed company RAGT that gives it access to elite wheat genetics for Europe, with the aim of building a commercial hybrid wheat business that could generate annual sales of up to EUR 1 billion within a decade of launch.
The programme is slated to start in the early 2030s, initially in Europe and North America. In Europe, Bayer plans to focus on winter wheat, while in North America it will sell winter and spring varieties under the WestBred brand. The company says hybrid wheat can lift yields by around 10 percent versus conventional seed, a potentially meaningful advantage in a global market with more than 220 million hectares under wheat and a crop that provides calories for about 30 percent of the world’s population.
Bayer said the agreement builds on a partnership with RAGT that has existed since 2021. The new licence combines RAGT’s genetics with Bayer’s breeding work, crop protection portfolio and digital tools. The target is ambitious, but the timeline is long: Bayer expects a full commercial roll-out in Europe and North America in the early 2030s, with annual revenue of up to EUR 1 billion by the mid-2040s.
The move also places Bayer in a race that is already heating up. Syngenta unveiled its own scalable hybrid wheat programme for Europe earlier in 2026, intensifying competition in seed genetics. The broader crop-protection battle is not cooling either, with Syngenta currently suing BASF in Delaware over alleged patent infringement tied to a new maize herbicide.
Should investors sell immediately? Or is it worth buying Bayer?
At the same time, Fitch has opted not to follow Bayer’s recent legal progress with a ratings upgrade. The agency reaffirmed the company’s BBB credit rating and kept the outlook negative, citing operational uncertainty and the group’s heavy debt load as ongoing risks. That stance came even after Bayer won at the US Supreme Court at the end of June in Monsanto v Durnell, where the justices voted seven to two to block state-level lawsuits over missing cancer warnings on Roundup labels, provided the US Environmental Protection Agency does not require such a warning.
The ruling trimmed Bayer’s legal exposure, but it did not alter Fitch’s view of the credit story. For the agency, debt remains the central issue. Bayer has been working for years to ease pressure from the billions of euros tied to US litigation, making access to capital an important part of the strategy. In that regard, the company also recently placed USD 5 billion of bonds, a sign that market funding remains available despite the negative outlook.
Shares have eased back from their highs. On Thursday, Bayer closed at EUR 47.60, or EUR 47.74, depending on the reference point used in the market data cited this week. Either way, the stock is just over 11 percent below the 52-week peak of EUR 53.86 reached in early July. Even so, it remains up more than 72 percent over the past year and is still clearly above the levels seen before the recent recovery.
The company is now in a quiet period until the half-year results on 4 August, which means management will not comment publicly on business developments before then. Analysts remain split. Jefferies’ Michael Leuchten kept a Hold rating and a EUR 46 target on 13 July, pointing to debt and continuing cash outflows. UBS’s Matthew Weston stayed at Buy with a EUR 52 target on the same day, arguing that the hearing on the Roundup class-settlement matter scheduled for 19 August could become a fresh catalyst.
Bayer at a turning point? This analysis reveals what investors need to know now.
Berenberg also turned more constructive, lifting its price target from EUR 40.50 to EUR 55 while leaving the rating at Hold. Its analyst sees the latest legal wins, including Durnell and the remand of a hearing in the Missouri settlement case, as potential steps toward a split of the group’s crop science and pharmaceutical businesses.
For now, Bayer is being pulled in two directions: a promising, but distant, hybrid wheat opportunity on one side, and Fitch’s warning about leverage on the other. The next checkpoints are the half-year figures on 4 August and the hearing on 19 August. Until then, the stock is likely to keep trading in the space between EUR 46 and EUR 55.
Ad
Bayer Stock: New Analysis - 17 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
